Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.41 |
| ▸ | KDR | P35968 | 9/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 6/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12755258 | 0.80 | PIK3CA (0.54) | LCKBRAFSCN10A | |
| SCHEMBL25449359 | 0.79 | ADORA1 (0.43) | LCKBRAFSCN10A | |
| SCHEMBL25449348 | 0.79 | CCR9 (0.43) | BRAFCCR9SCN10A | |
| SCHEMBL25449363 | 0.78 | SCN10A (0.40) | KDRBRAFKCNH2SCN10A | |
| SCHEMBL18177013 | 0.77 | SCN10A (0.39) | LCKKDRMAPK14JAK3KCNH2 | |
| SCHEMBL4548606 | 0.77 | SCN10A (0.39) | LCKKDRKCNH2SCN10AMETAP2 | |
| SCHEMBL14724666 | 0.77 | CYP1A2 (0.46) | LCKKDRMAPK14BRAFTEK | |
| SCHEMBL14724690 | 0.76 | LCK (0.39) | LCKKDRMAPK14BRAFTEK | |
| SCHEMBL1585490 | 0.76 | EGFR (0.44) | LCKKDRMAPK14BRAFJAK3 | |
| SCHEMBL179533 | 0.76 | LCK (0.52) | LCKKDRMAPK14JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | LCK 4271/4885KDR 4379/4885MAPK14 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.